A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
A phase 3 trial of Epcoritamab in diffuse large b-cell lymphoma, run by Genmab, active and no longer recruiting.
Overview
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China is a phase 3 interventional study registered as NCT07226752 by Genmab, with 72 participants enrolled, started 2022-10-08 and due to reach its primary completion in 2025-10-13. Interventions recorded: Epcoritamab, Investigator's Choice Chemotherapy. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr
Shares Epcoritamab, Genmab, Diffuse large B-cell lymphoma.
- TrialEPCORE DLBCL-2
Shares Epcoritamab, Diffuse large B-cell lymphoma.
- TrialA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita
Shares Epcoritamab, Genmab, Diffuse large B-cell lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab.
- TrialTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Shares Epcoritamab, Genmab, Diffuse large B-cell lymphoma.
- TrialEPCORE DLBCL-1
Shares Epcoritamab, Diffuse large B-cell lymphoma.
- IdeactDNA-guided escalation and de-escalation in frontline DLBCL
Shares Epcoritamab, Diffuse large B-cell lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab.